The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) is a huge mover today! About 518,312 shares traded hands. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 120.62% since March 8, 2016 and is uptrending. It has outperformed by 111.30% the S&P500.
The move comes after 6 months positive chart setup for the $481.13 million company. It was reported on Oct, 11 by Barchart.com. We have $22.06 PT which if reached, will make NASDAQ:PTCT worth $288.68 million more.
Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on November, 14. They expect $-1.19 earnings per share, up 6.30% or $0.08 from last year’s $-1.27 per share. After $-1.14 actual earnings per share reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 4.39% negative EPS growth.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage
Out of 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 2 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 29% are positive. $135 is the highest target while $6 is the lowest. The $48.71 average target is 253.23% above today’s ($13.79) stock price. PTC Therapeutics has been the topic of 16 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm earned “Hold” rating on Friday, October 23 by Jefferies. On Wednesday, February 24 the stock rating was upgraded by Jefferies to “Hold”. The company was downgraded on Wednesday, February 24 by Citigroup. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Buy” rating given on Tuesday, August 25 by Citigroup. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, October 16. RBC Capital Markets downgraded the shares of PTCT in a report on Wednesday, February 24 to “Sector Perform” rating. As per Friday, July 31, the company rating was maintained by RBC Capital Markets. The rating was maintained by Oppenheimer with “Outperform” on Thursday, February 25. Credit Suisse initiated PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, January 20 with “Outperform” rating. The rating was downgraded by Credit Suisse to “Neutral” on Tuesday, July 26.
According to Zacks Investment Research, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.”
Insitutional Activity: The institutional sentiment increased to 1.23 in Q2 2016. Its up 0.40, from 0.83 in 2016Q1. The ratio increased, as 17 funds sold all PTC Therapeutics, Inc. shares owned while 30 reduced positions. 17 funds bought stakes while 41 increased positions. They now own 28.13 million shares or 3.23% less from 29.06 million shares in 2016Q1.
The New York-based Jennison Assocs Limited Co has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Bnp Paribas Arbitrage holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 1,197 shares. Alliancebernstein L P holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 75,650 shares. Susquehanna Llp holds 0% or 104,188 shares in its portfolio. Davenport Communication Lc has 0% invested in the company for 82,200 shares. The Connecticut-based Tudor Inv Corp Et Al has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Blackrock Institutional Na holds 0% or 812,757 shares in its portfolio. Savings Bank Of New York Mellon Corporation holds 0% or 150,068 shares in its portfolio. Credit Suisse Ag last reported 0% of its portfolio in the stock. Meeder Asset Mgmt, a Ohio-based fund reported 12,183 shares. Cornerstone Advisors has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Federated Invsts Pa holds 0% or 16,868 shares in its portfolio. Frontier Mgmt Co Limited Company owns 1.43 million shares or 0.08% of their US portfolio. D E Shaw & Com holds 0% or 28,761 shares in its portfolio. Moreover, Blackrock Fund has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 1.30M shares.
More news for PTC Therapeutics, Inc. (NASDAQ:PTCT) were recently published by: Fool.com, which released: “Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday” on September 20, 2016. Prnewswire.com‘s article titled: “PTC Therapeutics Announces New Analyses that Support the Potential Benefit of …” and published on October 06, 2016 is yet another important article.
PTCT Company Profile
PTC Therapeutics, Inc., incorporated on March 31, 1998, is a biopharmaceutical firm focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older in over 30 member states of the European Economic Area (EEA). It holds commercialization rights to Translarna for all indications in all territories, across the world. Translarna is designated as an orphan medicinal product for the treatment of cystic fibrosis (CF), duchenne muscular dystrophy (DMD), Mucopolysaccharidosis type I (MPS I), and aniridia. The Company’s programs include Translarna for nmDMD, Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.